Literature DB >> 3437063

Pharmacokinetics of nifedipine after oral administration in chronic liver disease.

M D Ene1, C J Roberts.   

Abstract

Presented are the results of a study in which ten healthy subjects and seven patients with hepatic cirrhosis were given 10 mg nifedipine orally; plasma concentrations of the drug were measured over 24 hours. The drug was also administered intravenously, but those results were unsatisfactory for presentation. The rate of absorption and peak plasma concentrations were similar in the two groups. There was a fourfold increase in the elimination half-life (434 +/- 74 minutes in the cirrhotics compared with 102 +/- 11 minutes in the healthy subjects). A twofold increase in the area under the plasma concentration-time curve occurred in the cirrhotic group. The study confirmed that there is clinically significant alteration in the kinetics of nifedipine in patients who have hepatic cirrhosis and that there is considerable risk of accumulation. No adverse effects were observed despite high plasma levels of nifedipine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3437063     DOI: 10.1002/j.1552-4604.1987.tb05604.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Authors:  Trevor N Johnson; Koen Boussery; Karen Rowland-Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 2.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 3.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

4.  Elevated plasma nilvadipine concentration after single and chronic oral administration to patients with chronic liver disease.

Authors:  Y Takata; T Yoshizumi; Y Ito; M Kikuchi; M Ueno; A Tsukashima; K Kobayashi; M Fujishima
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 6.  P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.

Authors:  M Murray
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

7.  Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis.

Authors:  Daniela Gabbia; Arianna Dalla Pozza; Laura Albertoni; Roberta Lazzari; Giorgia Zigiotto; Maria Carrara; Vincenzo Baldo; Tatjana Baldovin; Annarosa Floreani; Sara De Martin
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.